Artemisinin News and Research RSS Feed - Artemisinin News and Research

Artemisinin is a drug used to treat multi-drug resistant strains of falciparum malaria. The compound (a sesquiterpene lactone) is isolated from the plant Artemisia annua. Not all plants of this species contain artemisinin.
WHO calls on global health community to address significant gaps in prevention, treatment of malaria

WHO calls on global health community to address significant gaps in prevention, treatment of malaria

WHO is calling on the global health community to urgently address significant gaps in the prevention, diagnosis and treatment of malaria. Despite dramatic declines in malaria cases and deaths since 2000, more than half a million lives are still lost to this preventable disease each year. [More]
Study explores artemisinin resistance in Plasmodium falciparum malaria

Study explores artemisinin resistance in Plasmodium falciparum malaria

According to the World Health Organization's 2014 World Malaria Report, there are an estimated 198 million cases of malaria worldwide with 3.3 billion people at risk for contracting the infection. Although the impact of malaria is still significant, the statistics reflect a considerable reduction in the global malaria burden. Since 2010, disease transmission has been reduced by 30 percent and mortality due to malaria has decreased by almost half. [More]
Malaria parasites with Ap2mu gene mutation less sensitive to antimalarial drug artemisinin

Malaria parasites with Ap2mu gene mutation less sensitive to antimalarial drug artemisinin

Early indicators of the malaria parasite in Africa developing resistance to the most effective drug available have been confirmed, according to new research published in Antimicrobial Agents and Chemotherapy. [More]
Canada-US researchers to jointly study effectiveness of AIO treatment in patients with late stage cancer

Canada-US researchers to jointly study effectiveness of AIO treatment in patients with late stage cancer

Canadian and American health-care professionals will work together to study the effectiveness of advanced integrative oncology (AIO) treatment for patients with late stage cancer. AIO treatment includes elements of conventional and naturopathic medicine. [More]

Scientists successfully produce highly effective medication for malaria from plant waste material

Professor Peter H. Seeberger, Professor Andreas Seidel-Morgenstern and their team are successful in producing a low-cost but highly effective medication for malaria from plant waste material. For their findings, they received the $25,000 award “Humanity in Science” during Pittcon 2015 in New Orleans. [More]

Two researchers win Humanity in Science prize for developing new antimalarial drug production methods

Prof. Dr. Peter H. Seeberger, a director at the Max Planck Institute of Colloids and Interfaces in Potsdam and a professor of chemistry at Freie Universität Berlin, and Prof. Dr.-Ing. Andreas Seidel-Morgenstern, a director at the Max Planck Institute for Dynamics of Complex Technical Systems in Magdeburg and a professor of chemical engineering at the Otto-von Guericke-University in Magdeburg, won the Humanity in Science prize for their groundbreaking work in developing new production methods for antimalarial drugs. [More]
Dengue fever circulating in urban areas of West Africa

Dengue fever circulating in urban areas of West Africa

Misdiagnosis of febrile illnesses as malaria is a continuing problem in Africa. A new study shows that in Ghana, dengue fever is circulating in urban areas and going undiagnosed. The authors of the study hope to use the findings to launch a widespread initiative to better understand acute undifferentiated febrile illnesses in West Africa. [More]
Study unveils genetic architecture that enables parasite to develop antimalarial drug resistance

Study unveils genetic architecture that enables parasite to develop antimalarial drug resistance

The largest genome-wide association study to date of the malaria parasite Plasmodium falciparum unveils a complex genetic architecture that enables the parasite to develop resistance to our most effective antimalarial drug, artemisinin. The results could help to improve early detection of emerging artemisinin resistance. [More]
NTU scientists discover how malaria parasite develops resistance towards front-line drugs

NTU scientists discover how malaria parasite develops resistance towards front-line drugs

Scientists from Nanyang Technological University have discovered exactly how the malaria parasite is developing resistance towards the most important front-line drugs used to treat the disease. [More]
Study finds that K13 gene mutations cause malaria drug resistance in Southeast Asia

Study finds that K13 gene mutations cause malaria drug resistance in Southeast Asia

Growing resistance to malaria drugs in Southeast Asia is caused by a single mutated gene inside the disease-causing Plasmodium falciparum parasite, according to a study led by David Fidock, PhD, professor of microbiology & immunology and of medical sciences (in medicine) at Columbia University Medical Center. [More]
Scientists report new family of selective molecules to combat causal agent of malaria

Scientists report new family of selective molecules to combat causal agent of malaria

Malaria is one of the most serious health problems worldwide, registering 200 million clinical cases and more than 600,000 attributable deaths per year, according to information from the World Health Organization in 2013. Given the emerging resistance to the standard treatment most widely used throughout the world, which is based on artemisinin and its analogs, there is a need for new antimalarial compounds. [More]
Malaria deaths decline by 54% in Africa, 47% worldwide

Malaria deaths decline by 54% in Africa, 47% worldwide

The number of people dying from malaria has fallen dramatically since 2000 and malaria cases are also steadily declining, according to the World Malaria Report 2014. Between 2000 and 2013, the malaria mortality rate decreased by 47% worldwide and by 54% in the WHO African Region - where about 90% of malaria deaths occur. [More]
GHIT Fund announces new grants to tackle malaria, chagas disease and dengue

GHIT Fund announces new grants to tackle malaria, chagas disease and dengue

The Global Health Innovative Technology Fund, a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, today announced seven grant investments totaling US$15.3 million to speed the development of promising drugs and vaccines to battle three insect-borne diseases-malaria, dengue and Chagas disease. [More]

Pharmaceuticals against malaria can now be produced from waste of plant-extraction

Research success through collaborative efforts of chemists and engineers from Berlin/Potsdam and Magdeburg. All of the best currently available pharmaceuticals against malaria can now be produced in pure form using a single process, even from the waste of the plant-extraction. [More]

CleveXel Pharma, Guilin Pharmaceutical partner to speed up development of anti-malarial products

CleveXel Pharma today announces that the company has entered into a new partnering agreement with Guilin Pharmaceutical, a Chinese company located in Shanghai, regarding the development of two new products. [More]
Scientists identify number of compounds to treat cancer could add to anti-malarial arsenal

Scientists identify number of compounds to treat cancer could add to anti-malarial arsenal

Scientists searching for new drugs to fight malaria have identified a number of compounds -- some of which are currently in clinical trials to treat cancer -- that could add to the anti-malarial arsenal. [More]
Sanofi, PATH announce delivery of first large-scale batches of antimalarial treatments

Sanofi, PATH announce delivery of first large-scale batches of antimalarial treatments

Sanofi and PATH today announced the delivery of the first large-scale batches of antimalarial treatments manufactured with a new semisynthetic artemisinin derivative to malaria-endemic countries in Africa. [More]
Combination therapy effective in treating drug-resistant malaria

Combination therapy effective in treating drug-resistant malaria

Resistance to artemisinin, the main drug to treat malaria, is now widespread throughout Southeast Asia, among the Plasmodium falciparum (P. falciparum) parasites that cause the disease and is likely caused by a genetic mutation in the parasites. [More]
Viewpoints: Abortion rights buffer; coming 'freakout' on health law; repercussions of malaria prevention

Viewpoints: Abortion rights buffer; coming 'freakout' on health law; repercussions of malaria prevention

A Unanimous Supreme Court: Abortion Rights Lose A Buffer
Yet on Thursday the Supreme Court, in McCullen v. Coakley, struck down that law for violating the First Amendment. [More]

Protein-kinase interactions offer a new way to fight antimalarial drug resistance

When it comes to the emergence of antimalarial drug resistance, it's not a question of 'if' but 'when'. In order to keep up with the quickly evolving Plasmodium parasite - the cause of malaria - new ways to treat and control the disease must be found. [More]
Advertisement
Advertisement